Nifty Pharma stocks were in fast lane on Wednesday tracking all market clues. The performance in pharma stocks comes after when the RBI Governor Shaktikanta Das announced term liquidity facility of Rs 50,000 crore for access to emergency health security. Nifty Pharma index has outperformed benchmark Nifty 50.
The Reserve Bank of India (RBI) governor Shaktikanta Das on Tuesday announced an on-tap liquidity window of Rs50,000cr to boost the provision of immediate liquidity for ramping up COVID related healthcare infrastructure and services in the country. The window has a tenor of 3 years at the repo rate of 4% and is being opened till March 31, 2022.
On one side, continued high incidence of Covid cases along with extended lockdowns in various states is likely to influence the market and on the other hand steady corporate earnings and positive management commentaries is likely to provide downside support to the market.
Pharma companies like Cipla and DR Reddys are out performing on the back of Covid issues resurfacing in India. Threefold increase in the production capacity as increased demand vaccines like Remdesivir has benefited these companies.
Today Nifty Pharma outperforms at 13,656.40 up by 421.65 points or 3.19 per cent. The index has touched an intraday high of 13,600.35 and intraday low of 13,210.50 during early trading session on Wednesday.
On the trading window, Lupin was the top bull skyrocketing by 8 per cent followed by Alkem Laboratories surging by nearly 4 per cent. Sun Pharma and Aurobindo Pharma spurted 3.7 per cent and 3.4 per cent respectively to lead the gains. Cadila Healthcare was trading bullish at Rs 583.85 per piece surging by 2.5 per cent. Dr Reddy’s and Torrent Pharma was on an upside note rose nearly by 2 per cent lifting the index. Nearly, 1.5 per cent jump each was recorded in Divis Laboratories and Cipla. Meanwhile, Biocon was marginally up.
Stock Covered in the news